Major Depressive Disorder With Mixed Features (RESOLVE2)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: August 23, 2011
Last updated: December 11, 2012
Last verified: December 2012
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Condition Intervention Phase
Major Depressive Disorder
Drug: Lurasidone 20 mg
Drug: Lurasidone 60 mg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Resource links provided by NLM:

Further study details as provided by Sunovion:

Primary Outcome Measures:
  • MADRS [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Mean change from baseline in MADRS total score after 6 weeks of treatment

Secondary Outcome Measures:
  • CGI-S [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Global severity assessed by the CGI-S score (depression)

Enrollment: 0
Study Start Date: January 2012
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lurasidone 20 mg Drug: Lurasidone 20 mg
Lurasidone 20 mg once daily orally in the evening
Other Name: Latuda
Experimental: Lurasidone 60 mg Drug: Lurasidone 60 mg
Lurasidone 60 mg once daily orally in the evening
Other Name: Latuda
Placebo Comparator: Placebo Drug: Placebo
Placebo once daily orally in the evening


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.

Subject is 18 to 75 years of age, inclusive. Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured Clinical Interview for DSM-IV Disorders - Clinical Trial version [SCID-CT]).

Subject is currently experiencing a major depressive episode (diagnosed by DSM-IV-TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050305):

  • Elevated, expansive mood
  • Inflated self-esteem or grandiosity
  • More talkative than usual or pressure to keep talking
  • Flight of ideas or subjective experience that thoughts are racing
  • Increase in energy or goal-directed activity (either socially, at work or school, or sexually)
  • Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
  • Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia) Subject has a rater-administered Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥ 26 at screening and both a rater-administered and self-rated (administered by computer) MADRS total score ≥ 26 at baseline.

Exclusion Criteria:

Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.

Subject has attempted suicide within the past 3 months. Subject has a lifetime history of any bipolar I manic or mixed manic episode. Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01423240

  Show 27 Study Locations
Sponsors and Collaborators
Study Director: Medical Director, MD Sunovion
  More Information

Responsible Party: Sunovion Identifier: NCT01423240     History of Changes
Other Study ID Numbers: D1050305 
Study First Received: August 23, 2011
Last Updated: December 11, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Sunovion:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders
Lurasidone Hydrochloride
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Antipsychotic Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Dopamine D2 Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin 5-HT2 Receptor Antagonists
Serotonin Agents
Serotonin Antagonists
Tranquilizing Agents processed this record on May 26, 2016